



## Clinical trial results:

### A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

#### Summary

EudraCT number	2019-003451-11
Trial protocol	BG PL FR DE BE CZ AT ES NL GB IT DK RO
Global end of trial date	05 May 2022

#### Results information

Result version number	v1
This version publication date	14 May 2023
First version publication date	14 May 2023

#### Trial information

##### Trial identification

Sponsor protocol code	TP0006
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04224688
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	UCB Biopharma SRL
Sponsor organisation address	Allée de la Recherche 60, Brussels, Belgium, 1070
Public contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com
Scientific contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 October 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 April 2022
Global end of trial reached?	Yes
Global end of trial date	05 May 2022
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Demonstrate the clinical efficacy of rozanolixizumab in maintenance of treatment in study participants with primary immune thrombocytopenia

Protection of trial subjects:

During the conduct of the study all participants were closely monitored.

Background therapy:

Background therapy as permitted in the protocol.

Evidence for comparator:

Not applicable

Actual start date of recruitment	03 June 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	China: 7
Country: Number of subjects enrolled	Poland: 3
Country: Number of subjects enrolled	Russian Federation: 6
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	Ukraine: 6
Country: Number of subjects enrolled	United States: 1
Worldwide total number of subjects	30
EEA total number of subjects	8

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	28
From 65 to 84 years	2
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study started to enroll study participants in June 2020 and terminated in May 2022.

### Pre-assignment

Screening details:

Participant Flow refers to the Randomized Set.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Participants received a fixed-unit starting dose of placebo subcutaneous (sc) infusion matched to rozanolixizumab Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of placebo sc infusion matched to rozanolixizumab Dose B every 2 weeks until Week 23. Participants were followed up to a maximum of Week 31.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received placebo at prespecified time points.

<b>Arm title</b>	Rozanolixizumab
------------------	-----------------

Arm description:

Participants received a fixed-unit starting dose of rozanolixizumab sc infusion equivalent to Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of rozanolixizumab sc infusion equivalent to Dose B every 2 weeks until Week 23. After protocol amendment 3, the starting dose was removed and the frequency of administration of the Dose B was changed to weekly. Participants were followed up to a maximum of Week 31.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received rozanolixizumab at prespecified time points.

<b>Number of subjects in period 1</b>	Placebo	Rozanolixizumab
Started	10	20
Completed	8	13
Not completed	2	7
Consent withdrawn by subject	1	3
COVID-19	-	1
Adverse event, not fatal	-	2
Lack of efficacy	1	1

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description: Participants received a fixed-unit starting dose of placebo subcutaneous (sc) infusion matched to rozanolixizumab Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of placebo sc infusion matched to rozanolixizumab Dose B every 2 weeks until Week 23. Participants were followed up to a maximum of Week 31.	
Reporting group title	Rozanolixizumab
Reporting group description: Participants received a fixed-unit starting dose of rozanolixizumab sc infusion equivalent to Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of rozanolixizumab sc infusion equivalent to Dose B every 2 weeks until Week 23. After protocol amendment 3, the starting dose was removed and the frequency of administration of the Dose B was changed to weekly. Participants were followed up to a maximum of Week 31.	

Reporting group values	Placebo	Rozanolixizumab	Total
Number of subjects	10	20	30
Age Categorical Units: participants			
<=18 years	0	1	1
Between 18 and 65 years	10	17	27
>=65 years	0	2	2
Age Continuous Units: years			
arithmetic mean	41.9	42.3	
standard deviation	± 14.5	± 15.7	-
Sex: Female, Male Units: participants			
Female	6	13	19
Male	4	7	11
Platelet count Units: *10 <sup>9</sup> /L			
arithmetic mean	14.10	14.65	
standard deviation	± 7.77	± 8.18	-

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received a fixed-unit starting dose of placebo subcutaneous (sc) infusion matched to rozanolixizumab Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of placebo sc infusion matched to rozanolixizumab Dose B every 2 weeks until Week 23. Participants were followed up to a maximum of Week 31.	
Reporting group title	Rozanolixizumab
Reporting group description:	
Participants received a fixed-unit starting dose of rozanolixizumab sc infusion equivalent to Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of rozanolixizumab sc infusion equivalent to Dose B every 2 weeks until Week 23. After protocol amendment 3, the starting dose was removed and the frequency of administration of the Dose B was changed to weekly. Participants were followed up to a maximum of Week 31.	

### Primary: Percentage of Participants With Durable Clinically Meaningful Platelet Response of $\geq 50 \times 10^9/L$ , for at least 8 out of 12 weeks during the last 12 weeks

End point title	Percentage of Participants With Durable Clinically Meaningful Platelet Response of $\geq 50 \times 10^9/L$ , for at least 8 out of 12 weeks during the last 12 weeks <sup>[1]</sup>
End point description:	
Percentage of Participants With Durable Clinically Meaningful Platelet Response of $\geq 50 \times 10^9/L$ , for at least 8 out of 12 weeks during the last 12 weeks were reported. Randomized Set consisted of all enrolled study participants who were randomized. No formal analysis was carried out as the program was terminated.	
End point type	Primary
End point timeframe:	
During the last 12 weeks (Week 13 to Week 25)	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: Only Descriptive analysis was planned to be reported for this endpoint.	

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Percentage of participants				
number (not applicable)	0	5.0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to first Clinically Meaningful Platelet Response (CMPR) of $\geq 50 \times 10^9/L$ : time from starting treatment to achievement of first response of $\geq 50 \times 10^9/L$

End point title	Time to first Clinically Meaningful Platelet Response (CMPR) of $\geq 50 \times 10^9/L$ : time from starting treatment to achievement of
-----------------	--

## End point description:

Time from starting treatment to achievement of first clinically meaningful platelet response of  $\geq 50 \times 10^9/L$  was defined as date of first clinically meaningful response - date of first treatment + 1. Randomized Set consisted of all enrolled study participants who were randomized. No formal analysis was carried out as the program was terminated. Median was calculated based upon the Kaplan-Meier estimate. The probability of participants achieving a CMPR did not reach 0.5 so the Kaplan-Meier median could not be estimated in the 'Placebo' arm and Kaplan-Meier CI could not be estimated in the 'rozanolixizumab' arm. -999 and 999 indicate not available for the upper and lower limit of 95% CI because no formal analysis was carried out as the program was terminated.

End point type	Secondary
----------------	-----------

## End point timeframe:

Time from starting treatment to achievement of first response of $\geq 50 \times 10^9/L$ (up to Week 25)
--

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Days				
median (confidence interval 95%)	999 (-999 to 999)	8.0 (-999 to 999)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Percentage of Participants with Clinically Meaningful Platelet Response of  $\geq 50 \times 10^9/L$  by Day 8**

End point title	Percentage of Participants with Clinically Meaningful Platelet Response of $\geq 50 \times 10^9/L$ by Day 8
-----------------	---

## End point description:

Clinically meaningful platelet response was defined as platelet count of  $\geq 50 \times 10^9/L$ . Randomized Set consisted of all enrolled study participants who were randomized. No formal analysis was carried out as the program was terminated.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline to Day 8
-------------------

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Percentage of participants				
number (not applicable)	10.0	45.0		



## Statistical analyses

No statistical analyses for this end point

### Secondary: Cumulative number of weeks with Clinically Meaningful Platelet Response of $\geq 50 \times 10^9/L$ over the 24-week Treatment Period

End point title	Cumulative number of weeks with Clinically Meaningful Platelet Response of $\geq 50 \times 10^9/L$ over the 24-week Treatment Period
-----------------	--

End point description:

Total number of weeks with platelet counts  $\geq 50 \times 10^9/L$  over the 24-week Treatment Period of the study (Week 1 to Week 25) were reported. Randomized Set consisted of all enrolled study participants who were randomized. No formal analysis was carried out as the program was terminated.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 1 up to Week 25

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Weeks				
median (full range (min-max))	0.0 (0 to 10)	1.0 (0 to 18)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with Response defined as platelet count $\geq 30 \times 10^9/L$ and at least doubling of baseline, at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding

End point title	Percentage of Participants with Response defined as platelet count $\geq 30 \times 10^9/L$ and at least doubling of baseline, at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding
-----------------	---

End point description:

Response was defined as platelet count  $\geq 30 \times 10^9/L$  and at least doubling of baseline, at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding. Randomized Set consisted of all enrolled study participants who were randomized. No formal analysis was carried out as the program was terminated.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline during Treatment Period (up to Week 25)

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Percentage of participants				
number (not applicable)	10.0	20.0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to first rescue therapy

End point title	Time to first rescue therapy
-----------------	------------------------------

End point description:

Time to first rescue therapy was defined as date of first rescue therapy use - date of first treatment + 1. Median was calculated based upon the Kaplan-Meier estimate. Randomized Set consisted of all enrolled study participants who were randomized. No formal analysis was carried out as the program was terminated. The probability of requiring rescue medication did not reach 0.5 so the Kaplan-Meier median could not be estimated. -999 and 999 indicate not available for the upper and lower limit of 95% CI because no formal analysis was carried out as the program was terminated.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to first rescue therapy (up to Week 25)

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Days				
median (confidence interval 95%)	999 (-999 to 999)	999 (-999 to 999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score

End point title	Change from Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score
-----------------	--

End point description:

ITP-PAQ version 1 is a 44 item disease-specific Health-Related Quality of Life questionnaire developed for use in adults with chronic ITP. It includes 10 scales as physical health: Symptoms (6 items), Bother (3 items), Fatigue (4 items), Activity (2 items); emotional health: Fear (5 items) and Psychological (5 items); quality of life (QOL): Work QOL (4 items), Social QOL (4 items), Women's Reproductive QOL (6 items) and Overall QOL (5 items). Each item is rated on a Likert-type scale containing 4 to 7 responses. All item scores are transformed to a 0 to 100 continuum and are weighted equally to derive individual scale scores and total score (0-100) is calculated as per formula: Sum of item scores within the

scale/raw sum range\*100. Higher scores indicate better health status. Randomized Set: enrolled study participants who were randomized. Number of Participants analyzed signifies participants evaluable for this endpoint. No formal analysis was carried out as program was terminated.

End point type	Secondary
End point timeframe:	
From Baseline during Treatment Period (up to Week 25)	

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	12		
Units: units on a scale				
arithmetic mean (standard deviation)	-0.5 (± 17.0)	4.2 (± 12.9)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With treatment-emergent adverse events (TEAEs)

End point title	Percentage of Participants With treatment-emergent adverse events (TEAEs)
-----------------	---

End point description:

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose. Safety set included all randomized study participants who received at least one dose of IMP.

End point type	Secondary
End point timeframe:	
From Baseline to end of Safety Follow-Up Period (up to Week 31)	

End point values	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Percentage of participants				
number (not applicable)	60.0	95.0		

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Percentage of Participants With TEAEs leading to withdrawal of investigational medicinal product (ie, study discontinuation)**

---

End point title	Percentage of Participants With TEAEs leading to withdrawal of investigational medicinal product (ie, study discontinuation)
-----------------	--

End point description:

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose. Safety set included all randomized study participants who received at least one dose of IMP.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to end of Safety Follow-Up Period (up to Week 31)

---

<b>End point values</b>	Placebo	Rozanolixizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	20		
Units: Percentage of participants				
number (not applicable)	0	10.0		

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Baseline to end of Safety Follow-Up Period (up to Week 31)

Adverse event reporting additional description:

TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose. TEAEs were analyzed for Safety Set.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Rozanolixizumab
-----------------------	-----------------

Reporting group description:

Participants received a fixed-unit starting dose of rozanolixizumab sc infusion equivalent to Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of rozanolixizumab sc infusion equivalent to Dose B every 2 weeks until Week 23. After protocol amendment 3, the starting dose was removed and the frequency of administration of the Dose B was changed to weekly. Participants were followed up to a maximum of Week 31.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received a fixed-unit starting dose of placebo sc infusion matched to rozanolixizumab Dose A on Day 1. Following the initial dose, participants received a fixed-unit dose of placebo sc infusion matched to rozanolixizumab Dose B every 2 weeks until Week 23. Participants were followed up to a maximum of Week 31.

Serious adverse events	Rozanolixizumab	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 20 (25.00%)	1 / 10 (10.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Investigations			
Platelet count decreased			
subjects affected / exposed	1 / 20 (5.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Head injury			
subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			

subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin injury			
subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia viral			

subjects affected / exposed	1 / 20 (5.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Rozanolixizumab	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 20 (90.00%)	6 / 10 (60.00%)	
Vascular disorders			
Haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 20 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	4	0	
Pyrexia			
subjects affected / exposed	6 / 20 (30.00%)	0 / 10 (0.00%)	
occurrences (all)	22	0	
Infusion site pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Asthenia			
subjects affected / exposed	1 / 20 (5.00%)	1 / 10 (10.00%)	
occurrences (all)	4	1	
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	2 / 20 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Oropharyngeal pain			
subjects affected / exposed	2 / 20 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Psychiatric disorders			

Insomnia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 10 (10.00%) 1	
Investigations Platelet count decreased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	12 / 20 (60.00%) 25	2 / 10 (20.00%) 2	
Somnolence subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Blood and lymphatic system disorders Hypofibrinogenaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Anaemia subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	0 / 10 (0.00%) 0	
Eye disorders Eye pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 3	0 / 10 (0.00%) 0	
Nausea subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3	0 / 10 (0.00%) 0	
Abdominal pain			



subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 10 (10.00%) 1	
Constipation subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 10 (10.00%) 1	
Abdominal distension subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Gingival bleeding subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 3	0 / 10 (0.00%) 0	
Skin and subcutaneous tissue disorders			
Urticaria subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	0 / 10 (0.00%) 0	
Petechiae subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 2	1 / 10 (10.00%) 2	
Blister subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Hirsutism subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Renal and urinary disorders			
Haematuria subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	0 / 10 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Myalgia subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 3	0 / 10 (0.00%) 0	
Arthralgia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 3	1 / 10 (10.00%) 1	
Infections and infestations			

Urinary tract infection subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 10 (10.00%) 1	
COVID-19 subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 10 (10.00%) 1	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	1 / 10 (10.00%) 1	
Pharyngitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1	
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 10 (10.00%) 4	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 November 2019	<p>The primary purpose of this substantial amendment (21 Nov 2019) was to incorporate the feedback from the United States Food and Drug Administration (FDA) received on 23 October 2019. In addition to updates to provide clarity and consistency within the protocol and administrative revisions, the following modifications were made:</p> <ul style="list-style-type: none"><li>• Added details on study stopping rules</li><li>• Added ADA postdose samples to facilitate clinical validation of drug tolerance in the ADA assay</li><li>• Eligibility criteria were modified to exclude participants with undiagnosed IgA deficiency and to include patients with moderate renal impairment.</li><li>• Updated rescue therapy to include any systemic increase in corticosteroids dose above the Baseline dose</li><li>• Included new wording specific to the predefined order of formal hypotheses testing and the sequence in which testing would be performed</li><li>• Added an additional estimand for a secondary endpoint</li><li>• Provided timing for obtaining IgG samples due to interference of other tests</li><li>• Country-specific requirements: – Information specific to Moldova was no longer applicable to the study. – Updates to Poland were made to align with Polish Health Authority's and Clinical Trial Facilitation Group recommendations regarding pregnancy testing.</li><li>• Added new wording that local guidelines should be followed regarding antibiotic prophylaxis in asplenic participants to remind investigators about the importance of antibiotic therapy in management of infections in splenectomized participants.</li></ul>
29 September 2020	<p>The primary reason for this substantial amendment (29 Sep 2020) was to incorporate changes in the endpoints and the statistical analysis section, and to incorporate agency-required local protocol amendments into 1 global protocol. The country-specific changes were incorporated in Protocol Amendment 2 Appendix. In addition to updates to provide clarity and consistency within the protocol and administrative revisions, the following modifications were made:</p> <ul style="list-style-type: none"><li>• Changed the number of additional participants that could be recruited into the study from 75 to 60 (maximum total sample size was changed from 105 to 90) based on revised sample size calculation method and assumptions</li><li>• Primary analysis (previously incorporated by local Protocol Amendments 1.1, 1.2, and 1.3)– Removed all reference to the Fisher's Exact test and included as a separate supplemental estimand – Added more details regarding the Cochran-Mantel-Haenszel test</li><li>• Added details to explain that the interim analysis was to have been conducted on combined data from TP0003 and TP0006, including amendment of the futility stopping rule</li><li>• Modified study eligibility criteria to include study participants who had failed or were intolerant to 2 or more prior ITP therapies per global implementation of an ANSM request and implement feedback received from the FDA</li><li>• Deleted or moved to "other efficacy endpoints" endpoints that did not measure different manifestation of the disease and provided redundant information</li><li>• Included additional "other" efficacy endpoints</li><li>• Provided additional wording for clarification on the action taken for study participants on the lowest dose level with a platelet count between <math>&gt;200 \times 10^9/L</math> and <math>&lt;400 \times 10^9/L</math> (previously incorporated by local Protocol Amendments 1.2 and 1.3).</li></ul>

29 September 2020	<p>This includes the continued information from Protocol Amendment 2 • Added that an independent Quantitative Clinical Pharmacologist/Modeling and Simulation Scientist may have access to the randomization code to review unblinded PK, platelet and serum IgG data to allow modelling activities to be started by an independent scientist • Included contingency measures during a pandemic and other exceptional circumstances • Increased the number of sites from 50 to 70 • Country-specific requirements: – United States and Canada only: Updated and clarified study stopping rule per FDA request – Japan only (previously incorporated by local Protocol Amendment 1.2):</p> <ul style="list-style-type: none"> <li>• Added instructions for serious adverse event (SAE) reporting (investigational device) and device deficiency reporting specific for Japan, in accordance with local regulations in Japan</li> <li>• Added chest X-ray assessment to early withdrawal (EW) visit and EOS visit to confirm safety at study termination</li> <li>• Added the T-SPOT test as a recommended interferon-gamma release assay (IGRA) test in addition to the QuantiFERON test</li> <li>• Included details on the consent requirements for participants aged &lt;20 years of age</li> <li>• Added exclusion criterion relative to partial splenic artery embolization as this procedure might have been used for treatment of ITP in Japan</li> <li>• Removed wording on use of cannabidiols and medicinal marijuana because these drugs are prohibited by law in Japan.</li> </ul>
03 December 2021	<p>The primary reason for this substantial amendment (03 Dec 2021) was to modify the dosing regimen of the study on the recommendation of the IDMC. Only 1 study participant was screened under Protocol Amendment 3, and this participant was not treated prior to study termination. Thus, this aCSR, including analysis of the data for this study, was based on the protocol under Amendment 2.</p>

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
24 March 2020	From 24 March 2020 through 04 June 2020, enrollment into the study was temporarily on hold due to the coronavirus disease 2019 (COVID-19) pandemic outbreak.	05 June 2020
19 November 2021	From 19 Nov 2021, enrollment into the study was temporarily suspended to allow for the development of a protocol amendment (#3) to change the dosing frequency from biweekly to weekly. Reactivation commenced in March 2022.	06 April 2022

Notes:

## Limitations and caveats

None reported